The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin

Summary

The objective of the trial is to investigate the effect of adherence to oral semaglutide dosing instructions on glycaemic control in people with type 2 diabetes, which are dysregulated on metformin and naïve to second line antidiabetic treatment.

Eligibility

Inclusion Criteria:

* Diagnosis of type 2 diabetes for at least 1 year.
* HbA1c of 53-75 mmol/mol at ???.
* Treated with metformin for at least 1 year.
* Can understand and read Danish.
* Can use a smartphone, as well as the devices used in the clinical trial.
* Signed informed consent.

Exclusion Criteria:

* HbA1c value recorded less than 3 months prior to inclusion in trial.
* Current or prior treatment with other glucose-lowering medications than metformin.
* Cardiovascular disease or kidney disease which would indicate use of other second line treatments such as SGLT2 inhibitors or s.c. GLP1 receptor agonists (see also current guidelines https://endocrinology.dk/nbv/diabetes-melitus/behandling-og-kontrol-af-type-2-diabetes/).
* Other types of diabetes than type 2 diabetes.
* Participation in other trials.
* Pregnancy or breastfeeding.
* Known retinopathy.
* Known allergy to semaglutide.
* Major surgery planned during the trial period.
* Cancer diagnosis within five years prior to inclusion.
* Personal or family history of medullary thyroid carcinoma.
* Multiple endocrine neoplasia syndrome type 2.
* Conditions, which the investigators deem to render the participant unfit for inclusion in the trial, including a physical or cognitive inability to participate in the trial.

Conditions2

Browse More Trials